ResMed (RMD) Stock Overview
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Risk Analysis
RMD passed our risk checks.
RMD Community Fair Values
Create NarrativeSee what 94 others think this stock is worth. Follow their fair value or set your own to get alerts.
ResMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$268.09 |
| 52 Week High | US$293.81 |
| 52 Week Low | US$199.92 |
| Beta | 0.83 |
| 1 Month Change | -1.33% |
| 3 Month Change | 3.94% |
| 1 Year Change | 11.70% |
| 3 Year Change | 20.61% |
| 5 Year Change | 46.47% |
| Change since IPO | 39,801.77% |
Recent News & Updates
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Sep 06
ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Aug 27Recent updates
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Sep 06ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Aug 27Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Jul 29Shareholders Would Enjoy A Repeat Of ResMed's (NYSE:RMD) Recent Growth In Returns
Jun 23Do ResMed's (NYSE:RMD) Earnings Warrant Your Attention?
Jun 11There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price
May 30ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly
May 18ResMed: Cornering The Market In Sleep Solutions
Apr 24ResMed Inc. (NYSE:RMD) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 15If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
Feb 26ResMed Inc.'s (NYSE:RMD) Share Price Not Quite Adding Up
Feb 14Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Feb 10ResMed: Snoozers Can Be Winners
Feb 01ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Jan 24ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price
Jan 13ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency
Jan 01ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20Why ResMed's Rally Is Just Getting Started
Sep 18ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03Shareholder Returns
| RMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.4% | -1.5% | -1.5% |
| 1Y | 11.7% | -3.4% | 14.4% |
Price Volatility
| RMD volatility | |
|---|---|
| RMD Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 10,600 | Mick Farrell | www.resmed.co.in |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution.
ResMed Inc. Fundamentals Summary
| RMD fundamental statistics | |
|---|---|
| Market cap | US$39.40b |
| Earnings (TTM) | US$1.40b |
| Revenue (TTM) | US$5.15b |
Is RMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMD income statement (TTM) | |
|---|---|
| Revenue | US$5.15b |
| Cost of Revenue | US$2.06b |
| Gross Profit | US$3.09b |
| Other Expenses | US$1.69b |
| Earnings | US$1.40b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 9.60 |
| Gross Margin | 59.99% |
| Net Profit Margin | 27.22% |
| Debt/Equity Ratio | 11.2% |
How did RMD perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 22:05 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 45 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| David Rescott | Baird |
| Matthew Taylor | Barclays |